Merck beats profit and sales expectations amid Keytruda strength, but provides mixed full-year outlookMarket Watch • 07/30/24
Merck beats earnings expectations -- raises sales outlook on strong demand for top drugs like KeytrudaCNBC • 07/30/24
Pfizer And Merck's Earnings Previews: Uncorrelated To Big Tech, And Growth StylesSeeking Alpha • 07/29/24
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial CarcinomaBusiness Wire • 07/26/24
Countdown to Merck (MRK) Q2 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 07/25/24
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for InfantsBusiness Wire • 07/23/24
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financingGlobeNewsWire • 07/16/24
Forget Nvidia: Billionaires Are Dumping It and Piling Into These 3 Surprising Value Stocks InsteadThe Motley Fool • 07/16/24